Pathogenic effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by expressed antiviral short hairpin RNAs

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 643-656

  Scott, Tristan ^a   Paweska, Janusz T ^b   Arbuthnot, Patrick ^a   Weinberg, Marc S ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOCAPSID PROTEIN; PLASMID VECTOR; SHORT HAIRPIN RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ESSENTIAL NUCLEOCAPSID GENE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NON STRUCTURAL S GENE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; RNA INTERFERENCE; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING;

BIOLOGICAL ASSAY; CYTOPATHOGENIC EFFECT, VIRAL; HEK293 CELLS; HUMANS; LUCIFERASES, RENILLA; RIFT VALLEY FEVER VIRUS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 84861662510     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2073     Document Type: Article

References (54)

1. Bishop DH, Calisher CH, Casals J, et al. Bunyaviridae. Intervirology 1980; 14:125-143. (Pubitemid 11155239)
2. Peters CJ, Liu CT, Anderson GW, Morrill JC, Jahrling PB. Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. Rev Infect Dis 1989; 11 Suppl 4:S743-S749.
3. Gerdes GH. Rift valley fever. Vet Clin North Am Food Anim Pract 2002; 18:549-555.
4. Miller BR, Godsey MS, Crabtree MB, et al. Isolation and genetic characterization of Rift Valley fever virus from Aedes vexans arabiensis, Kingdom of Saudi Arabia. Emerg Infect Dis 2002; 8:1492-1494. (Pubitemid 36008790)
5. Jupp PG, Kemp A, Grobbelaar A, et al. The 2000 epidemic of Rift Valley fever in Saudi Arabia: mosquito vector studies. Med Vet Entomol 2002; 16:245-252.
6. Shoemaker T, Boulianne C, Vincent MJ, et al. Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg Infect Dis 2002; 8:1415-1420. (Pubitemid 36008778)
7. Fagbo SF. The evolving transmission pattern of Rift Valley fever in the Arabian Peninsula. Ann N Y Acad Sci 2002; 969:201-204. (Pubitemid 35305412)
8. Gad AM, Hassan MM, el Said S, Moussa MI, Wood OL. Rift Valley fever virus transmission by different Egyptian mosquito species. Trans R Soc Trop Med Hyg 1987; 81:694-698.
9. Turell MJ, Bailey CL, Beaman JR. Vector competence of a Houston, Texas strain of Aedes albopictus for Rift Valley fever virus. J Am Mosq Control Assoc 1988; 4:94-96.
10. Lim DV, Simpson JM, Kearns EA, Kramer MF. Current and developing technologies for monitoring agents of bioterrorism and biowarfare. Clin Microbiol Rev 2005; 18:583-607. (Pubitemid 41504507)
11. Sidwell RW, Smee DF. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res 2003; 57:101-111. (Pubitemid 36254724)
12. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287:2391-2405. (Pubitemid 34493202)
13. Müller R, Poch O, Delarue M, Bishop DHL, Bouloy M. Rift valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J Gen Virol 1994; 75:1345-1352.
14. Collett MS. Messenger RNA of the M segment RNA of Rift Valley fever virus. Virology 1986; 151:151-156. (Pubitemid 16111055)
15. Giorgi C, Accardi L, Nicoletti L, et al. Sequences and coding strategies of the S RNAs of Toscana and Rift Valley fever viruses compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses. Virology 1991; 180:738-753.
16. Vialat P, Billecocq A, Kohl A, Bouloy M. The S segment of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J Virol 2000; 74:1538-1543. (Pubitemid 30044105)
17. Perrone LA, Narayanan K, Worthy M, Peters CJ. The S segment of Punta Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in the Syrian hamster and codes for a type I interferon antagonist. J Virol 2007; 81:884-892. (Pubitemid 46067913)
18. Kalveram B, Lihoradova O, Ikegami T. NSs protein of rift valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62. J Virol 2011; 85:6234-6243.
19. Le May N, Dubaele S, De Santis LP, Billecocq A, Bouloy M, Egly J-M. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 2004; 116:541-550. (Pubitemid 38264431)
20. Le May N, Mansuroglu Z, Léger P, et al. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 2008; 4:e13.
21. Bouloy M, Janzen C, Vialat P, et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 2001; 75:1371-1377. (Pubitemid 32094695)
22. Billecocq A, Spiegel M, Vialat P, et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 2004; 78:9798-9806. (Pubitemid 39187098)
23. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 2009; 5:e1000287.
24. Habjan M, Pichlmair A, Elliott RM, et al. NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 2009; 83:4365-4375.
25. Muller R, Saluzzo J-F, Lopez N, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995; 53:405-411.
26. Bird BH, Albarino CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008; 82:2681-2691. (Pubitemid 351329159)
27. Liu L, Celma C, Roy P. Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol J 2008; 5:82.
28. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-811. (Pubitemid 28099681)
29. Arbuthnot P. Harnessing RNA interference for the treatment of viral infections. Drug News Perspect 2010; 23:341-350.
30. Fowler T, Bamberg S, Moller P, et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005; 86:1181-1188. (Pubitemid 40485676)
31. Müller S, Gunther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother 2007; 51:2215-2218. (Pubitemid 46903121)
32. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of Guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193:1650-1657. (Pubitemid 43839469)
33. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375:1896-1905.
34. Flusin O, Vigne S, Peyrefitte CN, Bouloy M, Crance JM, Iseni F. Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin. Virol J 2011; 8:249.
35. Takeda A, Sugiyama K, Nagano H, et al. Identification of a novel RNA silencing suppressor, NSs protein of tomato spotted wilt virus. FEBS Lett 2002; 532:75-79. (Pubitemid 35375870)
36. Soldan SS, Plassmeyer ML, Matukonis MK, Gonzalez-Scarano F. La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA. J Virol 2005; 79:234-244. (Pubitemid 39648379)
37. Passman M, Weinberg M, Kew M, Arbuthnot P. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun 2000; 268:728-733. (Pubitemid 30150859)
38. Bertrand E, Castanotto D, Zhou C, et al. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 1997; 3:75-88. (Pubitemid 27030252)
39. Saayman S, Barichievy S, Capovilla A, Morris KV, Arbuthnot P, Weinberg MS. The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS ONE 2008; 3:e2602.
40. King P, Goodbourn S. The beta-interferon promoter responds to priming through multiple independent regulatory elements. J Biol Chem 1994; 269:30609-30615. (Pubitemid 24376547)
41. Jansen van Vuren P, Paweska JT. Laboratory safe detection of nucleocapsid protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA. J Virol Methods 2009; 157:15-24.
42. Grimm D, Wang L, Lee JS, et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 2010; 120:3106-3119.
43. Arbuthnot P. Harnessing RNA interference for the treatment of viral infections. Drug News Perspect 2010; 23:341-350.
44. Bird BH, Bawiec DA, Ksiazek TG, Shoemaker TR, Nichol ST. Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus. J Clin Microbiol 2007; 45:3506-3513. (Pubitemid 350156840)
45. Njenga MK, Paweska J, Wanjala R, et al. Using a field quantitative real-time PCR test to rapidly identify highly viremic Rift Valley fever cases. J Clin Microbiol 2009; 47:1166-1171.
46. Ikegami T, Won S, Peters CJ, Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 2006; 80:2933-2940. (Pubitemid 43346388)
47. Mansuroglu Z, Josse T, Gilleron J, et al. Nonstructural NSs protein of Rift Valley fever virus interacts with pericentromeric DNA sequences of the host cell, inducing chromosome cohesion and segregation defects. J Virol 2010; 84:928-939.
48. Mandell RB, Flick R. Rift Valley fever virus: an unrecognized emerging threat? Hum Vaccin 2010; 6:597-601.
49. Verbruggen P, Ruf M, Blakqori G, et al. Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II. J Biol Chem 2011; 286:3681-3692.
50. Grimm D, Kay MA. Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther 2007; 15:878-888. (Pubitemid 46621646)
51. ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 2006; 14:883-892. (Pubitemid 44743127)
52. Mcintyre GJ, Groneman JL, Yu YH, Tran A, Applegate TL. Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Res Ther 2011; 8:1.
53. Henry SD, van der Wegen P, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006; 14:485-493. (Pubitemid 44296093)
54. Gou D, Weng T, Wang Y, et al. A novel approach for the construction of multiple shRNA expression vectors. J Gene Med 2007; 9:751-763. (Pubitemid 47386860)